Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lowered by Credit Suisse Group from $78.00 to $59.00 in a research report released on Monday, October 29th. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
RARE has been the subject of a number of other research reports. SunTrust Banks upped their target price on shares of Ultragenyx Pharmaceutical to $83.00 and gave the stock a positive rating in a research report on Monday, August 20th. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a strong-buy rating to a buy rating in a research report on Wednesday, July 25th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $86.00 target price for the company in a research report on Wednesday, October 3rd. JPMorgan Chase & Co. set a $68.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a buy rating in a research report on Saturday, October 27th. Finally, Canaccord Genuity upped their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $90.00 and gave the stock a buy rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $75.95.
Shares of NASDAQ:RARE traded up $2.64 during midday trading on Monday, reaching $53.63. 406,910 shares of the company were exchanged, compared to its average volume of 646,419. Ultragenyx Pharmaceutical has a one year low of $41.67 and a one year high of $90.98. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -7.15 and a beta of 2.34.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative net margin of 508.70% and a negative return on equity of 40.10%. The firm had revenue of $11.80 million during the quarter, compared to analyst estimates of $11.97 million. During the same quarter in the prior year, the business earned ($1.87) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 5800.0% on a year-over-year basis. Equities research analysts anticipate that Ultragenyx Pharmaceutical will post -3.99 EPS for the current year.
In other news, CFO Shalini Sharp sold 6,700 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total value of $603,469.00. Following the completion of the sale, the chief financial officer now owns 56,828 shares in the company, valued at approximately $5,118,497.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Aliski sold 19,550 shares of the firm’s stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $72.49, for a total transaction of $1,417,179.50. Following the completion of the sale, the director now owns 72,610 shares of the company’s stock, valued at approximately $5,263,498.90. The disclosure for this sale can be found here. Insiders have sold 32,250 shares of company stock valued at $2,354,669 in the last quarter. 8.40% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $181,000. Pacer Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $222,000. Gideon Capital Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $303,000. Janney Montgomery Scott LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $313,000. Finally, Xact Kapitalforvaltning AB lifted its holdings in shares of Ultragenyx Pharmaceutical by 49.7% in the 1st quarter. Xact Kapitalforvaltning AB now owns 6,623 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 2,200 shares during the last quarter. Hedge funds and other institutional investors own 95.39% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Further Reading: Short Selling
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.